Abstract
Cardiovascular diseases are the most common cause of mortality and morbidity accounting for more than 40% of total mortality in Western countries, most of which is due to acute coronary syndromes (ACS), including ST and non- ST elevation myocardial infarction. An optimal pharmacological approach in these patients is of major importance with a particular emphasis on the antiplatelet regimen, which remains the cornerstone of the initial ACS treatment at hospital admission and during percutaneous coronary interventions (PCI). This review briefly discusses the pathogenesis of ACS, and updates the available pharmacological antithrombotic strategies with a particular focus on aspirin and clopidogrel resistance, which has caused major concern, especially in the modern era of interventional cardiology. Persistent platelet reactivity despite aspirin or clopidogrel intake is probably a risk factor for the recurrence of ischemic events. Despite a lack of uniformly accepted definitions of aspirin and clopidogrel resistance, we provide an objective description of what is already proved and what remains to be established. In clopidogrel poor-responders, preliminary data suggest that increasing the loading dose might be beneficial prior to PCI, while trials on the potential benefit of an increased maintenance dose after PCI are ongoing. Overall, data on the mechanisms and the management of platelet hyperactivity or antiplatelet drug biological resistance are still scarce and further studies are needed.
Keywords: Acute coronary syndromes, aspirin, clopidogrel, resistance
Current Vascular Pharmacology
Title: Acute Coronary Syndrome and its Antithrombotic Treatment: Focus on Aspirin and Clopidogrel Resistance
Volume: 7 Issue: 2
Author(s): Robert F. Bonvini, Jean-Luc Reny, Francois Mach, Thomas Zeller and Pierre Fontana
Affiliation:
Keywords: Acute coronary syndromes, aspirin, clopidogrel, resistance
Abstract: Cardiovascular diseases are the most common cause of mortality and morbidity accounting for more than 40% of total mortality in Western countries, most of which is due to acute coronary syndromes (ACS), including ST and non- ST elevation myocardial infarction. An optimal pharmacological approach in these patients is of major importance with a particular emphasis on the antiplatelet regimen, which remains the cornerstone of the initial ACS treatment at hospital admission and during percutaneous coronary interventions (PCI). This review briefly discusses the pathogenesis of ACS, and updates the available pharmacological antithrombotic strategies with a particular focus on aspirin and clopidogrel resistance, which has caused major concern, especially in the modern era of interventional cardiology. Persistent platelet reactivity despite aspirin or clopidogrel intake is probably a risk factor for the recurrence of ischemic events. Despite a lack of uniformly accepted definitions of aspirin and clopidogrel resistance, we provide an objective description of what is already proved and what remains to be established. In clopidogrel poor-responders, preliminary data suggest that increasing the loading dose might be beneficial prior to PCI, while trials on the potential benefit of an increased maintenance dose after PCI are ongoing. Overall, data on the mechanisms and the management of platelet hyperactivity or antiplatelet drug biological resistance are still scarce and further studies are needed.
Export Options
About this article
Cite this article as:
Bonvini F. Robert, Reny Jean-Luc, Mach Francois, Zeller Thomas and Fontana Pierre, Acute Coronary Syndrome and its Antithrombotic Treatment: Focus on Aspirin and Clopidogrel Resistance, Current Vascular Pharmacology 2009; 7 (2) . https://dx.doi.org/10.2174/157016109787455662
DOI https://dx.doi.org/10.2174/157016109787455662 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Intestinal Fatty acid Absorption
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Oxidative Stress and Neurodegenerative Diseases: A Review of Upstream and Downstream Antioxidant Therapeutic Options
Current Neuropharmacology Gender Differences in Response to Therapy for Cardiovascular Diseases
Current Pharmacogenomics and Personalized Medicine Potential Approaches to Enhance the Effects of Estrogen on Senescent Blood Vessels and Postmenopausal Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry How Effective are the Lipid Modifying Medicines at Preventing Coronary Heart Disease in Patients with Type 2 Diabetes?
Vascular Disease Prevention (Discontinued) Role of Opioid Antagonists in the Treatment of Women with Glucoregulation Abnormalities
Current Pharmaceutical Design Lipid Management and Peripheral Arterial Disease
Current Drug Targets Reductive Stress: A New Concept in Alzheimer’s Disease
Current Alzheimer Research Treatment Strategies of Obsessive-Compulsive Disorder and Panic Disorder/Agoraphobia
Current Topics in Medicinal Chemistry Extracellular Matrix Scaffolds for Tissue Engineering and Regenerative Medicine
Current Stem Cell Research & Therapy Prevalence of Diabetes Among Immigrants in the Nordic Countries
Current Diabetes Reviews Ruthenium as an Effective Nitric Oxide Scavenger
Current Topics in Medicinal Chemistry Assessment of Acute Coronary Syndromes: Focus on Novel Biomarkers
Current Medicinal Chemistry Peroxisome Proliferator-Activated Receptor γ Agonists as Insulin Sensitizers: From the Discovery to Recent Progress
Current Topics in Medicinal Chemistry Ghrelin as a Potential Anti-Obesity Target
Current Pharmaceutical Design Medical Management of the Diabetic Patient with Coronary Artery Disease
Current Pharmaceutical Design Subject Index to Volume 10
Current Pharmaceutical Design Therapeutic Potential of Endothelial Progenitor Cells for Cardiovascular Diseases
Current Vascular Pharmacology Value of Abnormal Fetal Cardiac Axis in the Fetal Congenital Heart Disease
Current Medical Imaging Flavonoids and Chagas' Disease: The Story So Far!
Current Topics in Medicinal Chemistry